Biotech Values

[DewDiligence]

ALKS/CEPH – Here’s an example of the drivel
that passes for serious analysis on SeekingAlpha:

http://biz.yahoo.com/seekingalpha/070604/37202_id.html?.v=1

>>
Vivitrol has the potential to be a huge blockbuster, changing the way alcoholism is treated for the future. However, ALKS and its marketing partner Cephalon need to do a better job marketing this new treatment option.
<<

This is BS. Vivitrol is a dog. In all likelihood, it will remain a dog. It is currently selling at an annualized rate of $12M. CEPH misjudged badly to pay as much as they did to license it. Give credit to ALKS’ Richard Pops for a splendid sales job to get CEPH hooked.